Latest News

While we enjoy watching the progress our portfolio companies make, we appreciate this does not come easily and requires large measures of expertise, intuition, ingenuity and perseverance. This understanding increases our satisfaction in bringing you news of their accomplishments.

Use the filters above to refine results
18th November 2021

Novo Nordisk to Acquire Dicerna

10th November 2021

Valneva Announces European Commission Approval of Advance Purchase Agreement for up to 60 Million Doses of Inactivated COVID-19 Vaccine VLA2001

9th November 2021

Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy

8th November 2021

Abingworth appoints Jayson Punwani as Partner

1st November 2021

Venatorx Pharmaceuticals Announces Collaboration with Roche to Develop New Class of Antibiotics targeting WHO Critical Priority Pathogen

27th October 2021

Abingworth portfolio company GammaDelta Therapeutics to be acquired by Takeda

18th October 2021

Paratek Pharmaceuticals Announces Enrollment of First Patient in Phase 2b Study Evaluating NUZYRA® (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc)

18th October 2021

Atsena Therapeutics Unveils XLRS Gene Therapy Program Leveraging Novel Spreading Capsids

18th October 2021

Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial

18th October 2021

Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001

14th October 2021

Tizona Initiates Phase 1b Expansion Study of TTX-080 in Advanced Refractory or Resistant Malignancies

12th October 2021

GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa

29th September 2021

NuCana receives Fast Track Designation from the FDA for Acelarin (NUC-1031) for the Treatment of Biliary Tract Cancer

24th September 2021

Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy

20th September 2021

Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Two New Board Members

16th September 2021

Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing to Develop Next-Generation Non-viral Gene Therapies

16th September 2021

Nouscom announces initial results from Phase 1 trial for NOUS-209, an 'off-the-shelf' neoantigen cancer vaccine, in MSI-H solid tumors

15th September 2021

GammaDelta Therapeutics Initiates First-in-Human Phase 1 Trial of GDX012 for the Treatment of Acute Myeloid Leukaemia

15th September 2021

Abingworth strengthens investment team with new appointments in the US and UK

9th September 2021

Avillion announces positive results in MANDALA and DENALI Phase III trials of AstraZeneca’s PT027, a fixed-dose combination of albuterol and budesonide, demonstrating significant benefits for asthma patients

8th September 2021

HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate

25th August 2021

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies | eFFECTOR Therapeutics

24th August 2021

Nouscom announces first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer

10th August 2021

NuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer

5th August 2021

Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline

5th August 2021

Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate

4th August 2021

eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer

3rd August 2021

Q32 Bio Announces Appointment of Kathy LaPorte to its Board of Directors

2nd August 2021

Ipsen and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders

2nd August 2021

CymaBay Announces $100 Million Non-Dilutive Financing with Abingworth

15th July 2021

Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials, co-led by Abingworth

14th July 2021

Vera Therapeutics welcomes new CFO Sean Grant

8th July 2021

Scorpion Therapeutics announces new CEO Axel Hoos, M.D., PhD

7th July 2021

Delighted to share the appointment of Adam Cutler as CFO at Q32 Bio

28th June 2021

Atsena Therapeutics Receives Orphan Drug Designation from the FDA for Novel Gene Therapy to Treat Genetic Eye Disease LCA1

28th June 2021

Venatorx Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of VNRX-9945 for the Treatment of Chronic Hepatitis B Virus Infection

23rd June 2021

Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease

14th June 2021

We are pleased to share Atsena Therapeutics has appointed Kenji Fujita, MD, as Chief Medical Officer

10th June 2021

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China

3rd June 2021

Sierra Oncology Welcomes Two New Independent Directors to its Board

2nd June 2021

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a

27th May 2021

eFFECTOR Therapeutics and Locust Walk Acquisition Corp. announce merger agreement to create publicly listed, next-generation oncology company developing new class of cancer therapies

25th May 2021

Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH

14th May 2021

Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

13th May 2021

Vera Therapeutics Announces Pricing of Initial Public Offering

13th May 2021

Congratulations Brian Bock, newly appointed CFO of Exicure

10th May 2021

Abingworth raises $582 million for new Clinical Co-Development Fund – ACCD 2

6th May 2021

Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation

6th May 2021

Valneva Announces the Pricing of its Initial Public Offering on Nasdaq

30th April 2021

Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints

19th April 2021

Adaptate Biotherapeutics raises $18 Million in series A2 funding

9th April 2021

Congratulations Greg and team on the successful IPO of Reneo Pharma on Nasdaq (ticker: RPHM)

23rd March 2021

Delighted to share Reneo Pharmaceuticals has appointed Vineet R. Jindal as Chief Financial Officer

15th March 2021

Pleased to announce Reneo Pharmaceuticals has appointed Eric Dube, Ph.D. to its Board of Directors

11th March 2021

Nouscom receives approval to begin Phase 1b trials of NOUS-PEV, a novel personalized cancer immunotherapy

10th March 2021

Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate

9th March 2021

Exicure announces appointments of Elizabeth Garofalo, M.D., and Andrew Sassine to its Board of Directors

9th March 2021

We are delighted that Q32 Bio has appointed Dr. Jason Campagna as Chief Medical Officer

5th March 2021

Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors

17th February 2021

Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer

10th February 2021

Adicet Bio, Inc. Announces Pricing of $135 Million Public Offering of Common Stock and Concurrent Private Placement

8th February 2021

Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

3rd February 2021

Abingworth raises $465m for new life sciences fund Abingworth Bioventures 8

21st January 2021

Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer

19th January 2021

We are pleased to announce Vera Therapeutics has launched with an $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease

7th January 2021

Congratulations Gary Glick, CEO and the Scorpion Therapeutics team on an oversubscribed $162 million Series B financing